KeyBanc
https://www.key.com/html/LP-KBCM.htmlKeyBanc Capital Markets, a subsidiary of KeyCorp (NYSE: KEY), provides investment banking and capital markets services to middle-market companies.
-
KeyBanc's Asia Takeaways for Semiconductors: Most Positive for AMD, AVGO, MPWR
-
Marvell (MRVL) PT Lowered to $90 at KeyBanc
-
Why Nvidia's GTC could be a negative for Marvell and other optical stocks
-
KeyBanc: 'What to Watch for at NVDA GTC and MPWR Analyst Event'
-
Marvell (MRVL) PT Lowered to $115 at KeyBanc
-
6 chip stocks to consider for 2025 amid latest industry trends: KeyBanc
-
Marvell (MRVL) PT Raised to $135 at KeyBanc, Citing 'Robust Demand for AI'
-
KeyBanc on Semiconductors: 'Limited Signs of a Recovery in Analog, While AI Challenged by Cross Currents'
-
KeyBanc's Cloud Tracker Takeaways: 'General Server Demand Remains Solid, While New ARM Instances Continue to Ramp'
-
KeyBanc Raises Marvell (MRVL) PT to $125 as CEO Matt Murphy Declares He Is 'All In' on the Company
-
KeyBanc Reiterates Overweight Rating on Marvell (MRVL)
-
Marvell (MRVL) PT Raised to $95 at KeyBanc
-
KeyBanc hiked price targets on chipmakers as AI boom continues
-
KeyBanc rises price target on Nvidia stock, other chipmakers after positive China checks
-
Marvell (MRVL) PT Lowered to $90 at KeyBanc
-
3 stocks with a favorable risk/reward into earnings - KeyBanc
-
NVIDIA (NVDA) and AMD (AMD) stock targets cut at KeyBanc on softening demand trends
-
AMD (AMD) Tops KeyBanc's List of Semi Stocks to Own For 2022
-
UPDATE: Marvell (MRVL) PT Raised to $80 at KeyBanc
-
Marvell (MRVL) Closes the IPHI Acquisition, a Strategic and Tactical Win - KeyBanc
-
UPDATE: KeyBanc Starts Marvell (MRVL) at Overweight
-
Marvell Technology (MRVL): 3 Points From Non Deal Roadshow - Keybanc
-
Marvell (MRVL) PT Raised to $29 at KeyBanc Following 3Q; Reiterates Overweight
-
Notable Analyst Rating Changes for 11/20: STP, HES, DDS, LINTA Upgraded; PFG, CSX, VRSN, BOFL, D, ADCT Downgraded
-
David Moenning�s Daily State of the Markets: 8/28
-
Pre-Open Movers 5/27: Chemtura (CEM) Up on Takeover Reports, Favrille (FVRL) Sinks After Drug Fails

